Patents by Inventor Dirk Thye

Dirk Thye has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240108684
    Abstract: The disclosure features pharmaceutical compositions, methods, and kits featuring dosing regimens and CD101, or a pharmaceutical acceptable salt or neutral form thereof (e.g., CD101 acetate).
    Type: Application
    Filed: June 5, 2023
    Publication date: April 4, 2024
    Inventors: Kenneth BARTIZAL, Paul DARUWALA, Jeffrey Brian LOCKE, Voon ONG, Taylor SANDISON, Dirk THYE
  • Patent number: 11712459
    Abstract: The disclosure features pharmaceutical compositions, methods, and kits featuring dosing regimens and CD101, or a pharmaceutical acceptable salt or neutral form thereof (e.g., CD101 acetate).
    Type: Grant
    Filed: March 15, 2017
    Date of Patent: August 1, 2023
    Assignee: Cidara Therapeutics, Inc.
    Inventors: Kenneth Bartizal, Paul Daruwala, Jeffrey Brian Locke, Voon Ong, Taylor Sandison, Dirk Thye
  • Patent number: 10780144
    Abstract: The disclosure relates to methods of prophylactic and therapeutic treatments of a Pneumocystis infection (i.e., an infection caused by Pneumocystis jirovecii) in a subject by administering to the subject a compound of any of formulas (I)-(III) (e.g., a salt of Compound 1, or a neutral form thereof). The disclosure also relates to methods of inhibiting the replication of a Pneumocystis spp. The methods of the disclosure can be useful in immunocompromised subjects.
    Type: Grant
    Filed: August 1, 2019
    Date of Patent: September 22, 2020
    Assignee: Cidara Therapeutics, Inc.
    Inventors: Kenneth Bartizal, Paul Daruwala, Voon Ong, Maureen Roden, Taylor Sandison, Dirk Thye
  • Publication number: 20200164022
    Abstract: The disclosure relates to methods of prophylactic and therapeutic treatments of a Pneumocystis infection (i.e., an infection caused by Pneumocystis jirovecii) in a subject by administering to the subject a compound of any of formulas (I)-(III) (e.g., a salt of Compound 1, or a neutral form thereof). The disclosure also relates to methods of inhibiting the replication of a Pneumocystis spp. The methods of the disclosure can be useful in immunocompromised subjects.
    Type: Application
    Filed: August 1, 2019
    Publication date: May 28, 2020
    Inventors: Kenneth BARTIZAL, Paul DARUWALA, Voon ONG, Maureen RODEN, Taylor SANDISON, Dirk THYE
  • Patent number: 10369188
    Abstract: The disclosure relates to methods of prophylactic and therapeutic treatments of a Pneumocystis infection (i.e., an infection caused by Pneumocystis jirovecii) in a subject by administering to the subject a compound of any of formulas (1)-(111) (e.g., a salt of Compound 1, or a neutral form thereof). The disclosure also relates to methods of inhibiting the replication of a Pneumocystis spp. The methods of the disclosure can be useful in immunocompromized subjects.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: August 6, 2019
    Assignee: Cidara Therapeutics, Inc.
    Inventors: Kenneth Bartizal, Paul Daruwala, Voon Ong, Maureen Roden, Taylor Sandison, Dirk Thye
  • Publication number: 20190216885
    Abstract: The disclosure features pharmaceutical compositions, methods, and kits featuring dosing regimens and CD101, or a pharmaceutical acceptable salt or neutral form thereof (e.g., CD101 acetate).
    Type: Application
    Filed: March 15, 2017
    Publication date: July 18, 2019
    Inventors: Kenneth BARTIZAL, Paul DARUWALA, Jeffrey Brian LOCKE, Voon ONG, Taylor SANDISON, Dirk THYE
  • Publication number: 20190000917
    Abstract: The disclosure relates to methods of prophylactic and therapeutic treatments of a Pneumocystis infection (i.e., an infection caused by Pneumocystis jirovecii) in a subject by administering to the subject a compound of any of formulas (1)-(111) (e.g., a salt of Compound 1, or a neutral form thereof). The disclosure also relates to methods of inhibiting the replication of a Pneumocystis spp. The methods of the disclosure can be useful in immunocompromised subjects.
    Type: Application
    Filed: January 6, 2017
    Publication date: January 3, 2019
    Inventors: Kenneth BARTIZAL, Paul DARUWALA, Voon ONG, Maureen RODEN, Taylor SANDISON, Dirk THYE
  • Publication number: 20180303853
    Abstract: The present invention relates to compositions comprising ceftaroline or a prodrug thereof (e.g., ceftaroline fosamil) and methods for treating bacterial infections, such as complicated skin and structure infections (cSSSI) and community-acquired bacterial pneumonia (CABP) by administering ceftaroline or a prodrug thereof, (e.g., ceftaroline fosamil).
    Type: Application
    Filed: April 24, 2017
    Publication date: October 25, 2018
    Inventors: Dirk Thye, George Talbot
  • Publication number: 20180256673
    Abstract: The disclosure relates to methods of treating a fungal infection in a subject by administering to the subject a salt of Compound 1, or a neutral form thereof. The methods of the disclosure can be useful in subjects suffering from treatment resistant infections, useful in subjects who have previously failed treatment with an anti-fungal therapy, and useful for suppressing the emergence of resistant strains in infected subjects.
    Type: Application
    Filed: September 16, 2016
    Publication date: September 13, 2018
    Inventors: James Michael BALKOVEC, Kenneth BARTIZAL, Jeffrey Brian LOCKE, Voon ONG, Taylor SANDISON, Dirk THYE, David S. PERLIN, Kenneth Duke JAMES, Jr.
  • Patent number: 9629861
    Abstract: The present invention relates to compositions comprising ceftaroline or a prodrug thereof (e.g., ceftaroline fosamil) and methods for treating bacterial infections, such as complicated skin and structure infections (cSSSI) and community-acquired bacterial pneumonia (CABP) by administering ceftaroline or a prodrug thereof, (e.g., ceftaroline fosamil).
    Type: Grant
    Filed: May 27, 2015
    Date of Patent: April 25, 2017
    Assignee: FOREST LABORATORIES HOLDING LIMITED
    Inventors: Dirk Thye, George Talbot
  • Publication number: 20150258126
    Abstract: The present invention relates to compositions comprising ceftaroline or a prodrug thereof (e.g., ceftaroline fosamil) and methods for treating bacterial infections, such as complicated skin and structure infections (cSSSI) and community-acquired bacterial pneumonia (CABP) by administering ceftaroline or a prodrug thereof, (e.g., ceftaroline fosamil).
    Type: Application
    Filed: May 27, 2015
    Publication date: September 17, 2015
    Inventors: Dirk Thye, George Talbot
  • Publication number: 20110071114
    Abstract: The present invention relates to compositions comprising ceftaroline or a prodrug thereof (e.g., ceftaroline fosamil) and methods for treating bacterial infections, such as complicated skin and structure infections (cSSSI) and community-acquired bacterial pneumonia (CABP) by administering ceftaroline or a prodrug thereof, (e.g., ceftaroline fosamil).
    Type: Application
    Filed: September 21, 2010
    Publication date: March 24, 2011
    Applicant: FOREST LABORATORIES HOLDINGS LTD.
    Inventors: Dirk Thye, George Talbot
  • Patent number: 6645226
    Abstract: A tissue approximation device and processes for using the device are provided. The device is an implantable, biodegradable construct (except for hernia repairs) that has attachment points emanating from a supportive backing. The device improves the mechanical phase of wound healing and evenly distributes tension over the contact area between the device and tissue. Processes for using the device include wound closure, vascular anastomoses, soft tissue attachment and soft tissue to bone attachment.
    Type: Grant
    Filed: May 19, 2000
    Date of Patent: November 11, 2003
    Assignee: Coapt Systems, Inc.
    Inventors: Daniel Jacobs, Dirk Thye